Luke Corning - 15 Jun 2023 Form 4 Insider Report for Poseida Therapeutics, Inc.

Role
Director
Signature
/s/ Harry J.Leonhardt, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
15 Jun 2023
Net transactions value
$0
Form type
4
Filing time
16 Jun 2023, 16:07:34 UTC
Previous filing
16 Jun 2022
Next filing
18 Jun 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PSTX Common Stock Award $0 +19,650 +100% $0.000000 39,300 15 Jun 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PSTX Stock Option (Right to buy) Award $0 +27,350 $0.000000 27,350 15 Jun 2023 Common Stock 27,350 $2.47 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units granted pursuant to the Issuer's Equity Incentive Plan. The RSUs are scheduled to vest on the earlier to occur of (i) the one year anniversary of the date of grant and (ii) the day preceding the date of the next annual meeting of the Issuer's stockholders.
F2 The Reporting Person is no longer deemed to beneficially own shares held by Pentwater Capital Management LP, Crown Managed Accounts SPC, Investment Opportunities 3 SPC, LMA SPC on behalf of MAP 98 Segregated Portfolio, PWCM Master Fund Ltd., Oceana Master Fund, Ltd., Pentwater Merger Arbitrage Master Fund, Ltd., Pentwater Metric Merger Arbitrage Fund LP, Pentwater Credit Master Fund Ltd., Pentwater Equity Opportunities Master Fund, Ltd., or Pentwater Unconstrained Master Fund Ltd.
F3 The stock option will vest and become fully exercisable on the earlier to occur of (i) the one year anniversary of the date of grant and (ii) the day preceding the date of the next annual meeting of the Issuer's stockholders.